Beneficial effects of the sigma-1 agonist fluvoxamine for Tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: Report of 5 cases

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 14, Issue 6, 2012, Pages

  Albayrak, Yakup ^a   Hashimoto, Kenji ^b  

^a Kirklareli State Hospital   (Turkey)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; CHLORPROMAZINE; FLUPENTIXOL; FLUVOXAMINE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SIGMA 1 OPIATE RECEPTOR; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADULT; ANHEDONIA; APPETITE DISORDER; ARTICLE; CHOREA; CLINICAL ARTICLE; CONCENTRATION LOSS; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; DSM-IV; DYSTONIA; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MALE; OROFACIAL DYSKINESIA; PARANOID SCHIZOPHRENIA; PERSECUTORY DELUSION; PHYSICAL EXAMINATION; POSTPSYCHOTIC DEPRESSIVE DISORDER; POSTPSYCHOTIC DEPRESSIVE DISORDER OF SCHIZOPHRENIA; PSYCHOLOGIC ASSESSMENT; RESIDUAL SCHIZOPHRENIA; SCHIZOPHRENIA; SUICIDAL IDEATION; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84874886314     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.12br01401     Document Type: Article

References (28)

1. Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs newer antipsychotics in elderly patients. Am J Geriatr Psychiatry. 1999;7(1):70-76.
2. Laporta M, Archambault D, Ross-Chouinard A, et al. Articulatory impairment associated with tardive dyskinesia. J Nerv Ment Dis. 1990;178(10):660-662. doi:10.1097/00005053-199010000-00008
3. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995;18(3):197-214. doi:10.1097/00002826-199506000-00001
4. Schwartz M, Silver H, Tal I, et al. Tardive dyskinesia in northern Israel: preliminary study. Eur Neurol. 1993;33(3):264-266. doi:10.1159/000116951
5. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem. 2009;9(3):197-204.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington DC: American Psychiatric Association. 2000.
7. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.1136/jnnp.23.1.56
8. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Dept of Health, Education and Welfare; 1976:534-537.
9. Mulholland C, Cooper S. The symptoms of depression in schizophrenia and its management. Adv Psychiatr. 2000;6(3):169-177. doi:10.1192/apt.6.3.169
10. Siris SG. Depressive symptoms in the course of schizophrenia. In: DeLisi LE, ed. Depression in Schizophrenia. Washington, DC: American Psychiatric Press; 1990:3-23.
11. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000;61(suppl 4):5-9. doi:10.1007/s002130000670
12. Lavalaye J, Sarlet A, Booij J, et al. Dopamine transporter density in patients with tardive dyskinesia: a single photon emission computed tomography study. Psychopharmacology (Berl). 2001;155(1):107-109. doi:10.1007/s002130000670
13. Brasic JR, Bronson B. Tardive dyskinesia. medscape.com/article/1151826-overview. Accessed June 18, 2012.
14. Soares KV, McGrath JJ. The treatment of tardive dyskinesia-a systematic review and meta-analysis. Schizophr Res. 1999;39(1):1-16, discussion 17-18. doi:10.1016/S0920-9964(99)00021-3
15. Kenney C, Hunter C, Davidson A, et al. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48(3):379-384. doi:10.1177/0091270007312258
16. Ishikawa M, Ishiwata K, Ishii K, et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry. 2007;62(8):878-883. doi:10.1016/j.biopsych.2007.04.001
17. Gudelsky GA. Effects of sigma receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat. Eur J Pharmacol. 1995;286(3):223-228. doi:10.1016/0014-2999(95)00415-8
18. Alonso G, Phan V, Guillemain I, et al. Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system. Neuroscience. 2000;97(1):155-170. doi:10.1016/S0306-4522(00)00014-2
19. Furuse T, Hashimoto K. Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases. Ann Gen Psychiatry. 2010;9(1):17. doi:10.1186/1744-859X-9-17
20. Furuse T, Hashimoto K. Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors. Ann Gen Psychiatry. 2010;9(1):11. doi:10.1186/1744-859X-9-11
21. Cayköylü A, Albayrak Y, Uǧurlu GK, et al. Beneficial effects of fluvoxamine for hemiballism in a patient with depressive disorder: a case report. Acta Neurol Belg. 2011;111(1):62-65.
22. Albayrak Y, Ekinci O. Duloxetine associated tardive dyskinesia resolved by fluvoxamine: case report. J Clin Psychopharmacol. 2012. In press.
23. Schröder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem. 2005;74(1):739-789. doi:10.1146/annurev.biochem.73.011303.074134
24. Hayashi T, Tsai SY, Mori T, et al. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets. 2011;15(5):557-577.
25. Hayashi T, Su TP. An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand. Expert Opin Ther Targets. 2008;12(1):45-58. doi:10.1517/14728222.12.1.45
26. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des. 2006;12(30):3857-3876. doi:10.2174/138161206778559614
27. Lindholm D, Wootz H, Korhonen L. ER stress and neurodegenerative diseases. Cell Death Differ. 2006;13(3):385-392. doi:10.1038/sj.cdd.4401778
28. Doyle KM, Kennedy D, Gorman AM, et al. Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. J Cell Mol Med. 2011;15(10):2025-2039. doi:10.1111/j.1582-4934.2011.01374.x